Transpire Bio's ANDA for Generic High-Strength Trelegy Approved by the FDA

Overview

Transpire Bio Inc., a dynamic clinical-stage biopharmaceutical firm, has reached an important milestone on May 11, 2026. The company's abbreviated new drug application (ANDA) for a generic high-strength version of Trelegy® Ellipta®, a widely used medication for asthma and COPD, has been officially accepted for filing by the U.S. Food and Drug Administration (FDA).

Importance of Trelegy® Ellipta®

Trelegy® Ellipta® is significant in the treatment landscape for respiratory diseases. Designed to maintain asthma control in patients aged 18 and older, it also serves chronic obstructive pulmonary disease (COPD) patients effectively. In 2025, Trelegy® Ellipta® achieved impressive annual sales in the U.S. amounting to $8 billion, underscoring its popularity and need in the market.

The ANDA's Significance

Transpire Bio believes it is the pioneer company to file for this high-strength version of Trelegy® Ellipta® with a Paragraph IV certification, as per the Hatch-Waxman Act. If the ANDA receives FDA approval, the company anticipates securing 180 days of market exclusivity, which could provide a competitive advantage in making affordable respiratory treatments accessible to patients.

Leadership Insights

According to Dr. Xian-Ming Zeng, CEO of Transpire Bio, this acceptance signals a pivotal advancement in the company’s development trajectory, particularly as it strives to solidify its complex generic offerings. He stated, "Our adept team in South Florida continues to surpass expectations, ensuring we can soon offer affordable alternatives for asthma and COPD patients."

Dr. Abhishek Gupta, Chief Scientific Officer at Transpire Bio, echoed these sentiments. He articulated how the latest milestone illustrates the firm's strong capabilities in bringing complex drug-device combinations to market.

Expanding Horizons

Beyond its focus on Trelegy®, Transpire Bio is also dedicated to developing a pipeline of innovative inhalation therapies for conditions like Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), and more. The company is innovating solutions for Pulmonary Arterial Hypertension (PAH), diabetes, obesity, Parkinson's Disease psychosis, and glioblastoma, utilizing advanced manufacturing facilities located in South Florida.

Conclusion

The FDA’s acceptance of Transpire Bio’s ANDA for a generic Trelegy® Ellipta® reflects not only the company’s growing influence in the biopharmaceutical sector but also the continuing evolution in making essential treatments more accessible to those in need. This win showcases the effectiveness of the company's strategic approach to creating cost-effective alternatives in a market that has long been dominated by established medications.

For further details about Transpire Bio and its ongoing projects, visit www.transpirebio.com.